These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18653865)

  • 1. Leave regulation to the FDA.
    Hughes OC
    Science; 2008 Jul; 321(5888):490. PubMed ID: 18653865
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
    Marthaler AL
    Spec Law Dig Health Care Law; 1997 Sep; (223):9-45. PubMed ID: 10173273
    [No Abstract]   [Full Text] [Related]  

  • 3. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 4. Misbegotten preemptions.
    Kennedy D
    Science; 2008 May; 320(5876):585. PubMed ID: 18451268
    [No Abstract]   [Full Text] [Related]  

  • 5. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 6. Implications of the Lannett and Pharmadyne decisions.
    Vetrano AJ
    Am J Hosp Pharm; 1980 Apr; 37(4):537-40. PubMed ID: 7377217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 8. The Lohr decision: FDA perspective and position.
    Porter MJ
    Food Drug Law J; 1997; 52(1):7-11. PubMed ID: 10346705
    [No Abstract]   [Full Text] [Related]  

  • 9. Can FDA seek restitution or disgorgement?
    Gibbs JN; Fleder JR
    Food Drug Law J; 2003; 58(2):129-47. PubMed ID: 12866549
    [No Abstract]   [Full Text] [Related]  

  • 10. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 11. Section 8(c) of the proposed Restatement (Third) of Torts: is it really what the doctor ordered?
    Winchester JD
    Cornell Law Rev; 1997 Mar; 82(3):644-93. PubMed ID: 10343053
    [No Abstract]   [Full Text] [Related]  

  • 12. MedWatch, the new FDA adverse effects reporting system.
    Shader RI; Greenblatt DJ
    J Clin Psychopharmacol; 1993 Oct; 13(5):303-4. PubMed ID: 8227487
    [No Abstract]   [Full Text] [Related]  

  • 13. Judicial review of FDA preemption determinations.
    Frost A
    Food Drug Law J; 1999; 54(3):367-88. PubMed ID: 11797704
    [No Abstract]   [Full Text] [Related]  

  • 14. Statutory interpretation--federal Food, Drug, and Cosmetic Act--Third Circuit holds that the FDA can obtain restitution on behalf of consumers--United States v. Lane Labs-USA Inc., 427 F.3d 219 (3d Cir. 2005).
    Harv Law Rev; 2006 Jun; 119(8):2636-43. PubMed ID: 16830436
    [No Abstract]   [Full Text] [Related]  

  • 15. Sailing the straits of approval: the nature of FDA approval and its implications for surgeons.
    Reiter D
    Facial Plast Surg Clin North Am; 2007 May; 15(2):247-50, vii-viii. PubMed ID: 17544941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory watch: FDA PDUFA goals missed.
    Hay M
    Nat Rev Drug Discov; 2009 Jan; 8(1):10. PubMed ID: 19116619
    [No Abstract]   [Full Text] [Related]  

  • 17. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
    Burkhart CG
    J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
    [No Abstract]   [Full Text] [Related]  

  • 18. End of the line in sight for FDA?
    Nature; 1995 Aug; 376(6543):713-4. PubMed ID: 7651523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of approved drugs for unlabeled indications.
    Stratton WT
    Kans Med; 1993 Nov; 94(11):286. PubMed ID: 8309159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.